Obsidian Therapeutics, Inc.
Industry
- Biotechnology
- Large Molecule
- Gene Therapy, Cell Therapy
- Drug Discovery Technologies
- Pharmaceuticals
- Vaccines
Latest on Obsidian Therapeutics, Inc.
April began with a flurry of new venture capital mega-rounds of $100m or more – a $160.5m series C round for Obsidian Therapeutics, Inc. , a $132m series B for Alterome Therapeutics, Inc. and a $12
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ikena Cuts Back As BMS Unravels Partner
In the more than six years since the US Food and Drug Administration approved Novartis AG ’s Kymriah (tisagenlecleucel) and Kite Pharma’s – now part of Gilead Sciences, Inc. – Yescarta (axicabtagen
Research into the potential for tumor-infiltrating lymphocytes (TILs) as a personalized cancer therapy was first begun around 30 years ago, but the cell therapy’s time may finally have come. A new aca